Sign In
Buy XLRN
$178.75
+0 (+0%)
At Close: May 27, 2022
Acceleron to Webcast Second Quarter 2021 Financial Results on August 5, 2021
07:00am, Monday, 26'th Jul 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, August 5, 2021 at 5:00 p.m. EDT to discuss its second qua
BioNTech, CyberArk, Vertex Pharma and More Monday Afternoon Analyst Calls
11:50am, Monday, 19'th Jul 2021
With the trading day closing in on the halfway point, traders were feeling the heat as all the major indexes were ripping downward.
Ongoing Treatment With Acceleron's Sotatercept Continue To Show Benefit In PAH Patients
03:15pm, Wednesday, 19'th May 2021
Acceleron Pharma Inc (NASDAQ: XLRN) has announced interim results from the open-label extension of the PULSAR Phase 2 trial evaluating sotatercept in patients with pulmonary arterial hypertension (
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics t
Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q1 2021 Results - Earnings Call Transcript
04:48am, Sunday, 09'th May 2021
Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q1 2021 Results - Earnings Call Transcript
Acceleron Pharma (XLRN) Reports Q1 Loss, Misses Revenue Estimates
06:47pm, Thursday, 06'th May 2021
Acceleron (XLRN) delivered earnings and revenue surprises of 7.23% and -9.62%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Acceleron Announces First Quarter 2021 REBLOZYL® Net Sales
07:10am, Thursday, 29'th Apr 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics
Acceleron: Neutral On Stock Price Gains
09:43pm, Monday, 05'th Apr 2021
Acceleron's stock price is near a 52-week high. Reblozyl sales are growing rapidly.
Why Is Acceleron (XLRN) Up 0.5% Since Last Earnings Report?
12:41pm, Saturday, 27'th Mar 2021
Acceleron (XLRN) reported earnings 30 days ago. What's next for the stock?
Acceleron (XLRN) Stock Jumps 3.3%: Will It Continue to Soar?
12:06pm, Monday, 22'nd Mar 2021
Acceleron (XLRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Acceleron (XLRN) Q4 Loss Wider Than Expected, Revenues Beat
05:26pm, Monday, 01'st Mar 2021
Acceleron (XLRN) reports a wider loss in the fourth quarter of 2020 on higher costs and lower revenues.
Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q4 2020 Results - Earnings Call Transcript
09:05pm, Thursday, 25'th Feb 2021
Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q4 2020 Results - Earnings Call Transcript
Recap: Acceleron Pharma Q4 Earnings
05:00pm, Thursday, 25'th Feb 2021
Shares of Acceleron Pharma (NASDAQ:XLRN) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 115.91% year over year to ($0.95), which mis
Acceleron Announces Fourth Quarter and Full Year 2020 REBLOZYL® Net Sales
07:10am, Thursday, 04'th Feb 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics
5 Biotech Stocks That More Than Doubled This Year
09:47am, Monday, 21'st Dec 2020
The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.
